Books about Inhibitors from Amazon.com

View the Table of Contents.   Read the Introduction.

”Stirring firsthand account of the SSRI wars. . . . Healy is a distinguished research and practicing psychiatrist, university professor, frequent expert witness, former secretary of the British Association for Psychopharmacology, and author of three books in the field. Instead of shrinking from commercial involvement, he has consulted for, run clinical trials for, and at times even testified for most of the major drug firms. But when he pressed for answers to awkward questions about side effects, he personally felt Big Pharma's power to bring about a closing of ranks against troublemakers. That experience among others has left him well prepared to puncture any illusions about the companies' benevolence or scruples.”
—New York Review of Books

"A compelling story about mystery, deception, death, disappointment, vindication, and uncertainty."
—The American Psychological Association

"Healy confirms his status as one longtime thorn in the side of big drug companies, recounting how he was initially enthusiastic about SSRIs but eventually grew concerned about their side effects."
—Psychology Today

"Physicians should be aware of Let Them Eat Prozac."
—JAMA

"Let Them Eat Prozac is a double-pronged exploration, first of the SSRI drugs used to treat depression, and second of the drug industry."
—Publishers Weekly

"Ultimately, the book is about science, society and the power and misuse of commercial promotion. . . . His investigation is impressive."
—Nature

"This very important book will demonstrate beyond your worst dreams that the commercial needs of Big Pharma are the natural-born enemy of independent scientific research."
—John Le Carré

"Healy presents technical matters clearly. This book could not be more timely."
—Foreword

"Let Them Eat Prozac is an interesting history. It asks some stimulating and challenging questions, which are still in need of better and more constructive answers."
—Journal of the American Academy of Child Adolescent Psychiatry

"In a flood of academic publications and talks, David Healy has issued harsh criticisms of both the pharmaceutical industry in general and the nearly $20-billion-dollar-a-year antidepressant industry in particular."
—Boston Globe

"Healy does raise some timely issues."
—Psychiatric Services

"Dr. Healy's tenacity in fighting for what he believes in is admirable."
—E-Streams

"[Healy is] the leading authority on the history of psychopharmacology."
—Times Literary Supplement

“An alarming book. . . . The most disturbing part of the story Healy tells is not merely about the risks of SSRIs but about the efforts of the pharmaceutical industry to make sure those risks were not uncovered.”
—Dissent

"In his timely new book, Healy draws on his extensive experience in antidepressant studies and involvement in legal actions against drug manufacturers. . . . Healy has the advantage of access to internal pharmaceutical industry documents and makes a strong case."
—Library Journal

"The author is an excellent historian who offers a gripping interpretation of the role of the pharmaco-industrial complex in the introduction of SSRIs. His recommendation for a funded agency that would carefully evaluate the benefits and harms of marketed drugs is a superb idea and much needed."
—Jonathan Cole, Harvard Medical School

"Healy exposes the massive fraud and deception in the production and marketing of antidepressant drugs, the selevtive serotonin reuptake inhibitors (SSRIs)."
—Choice

Prozac. Paxil. Zoloft. Turn on your television and you are likely to see a commercial for one of the many selective serotonin reuptake inhibitors (SSRIs) on the market. We hear a lot about them, but do we really understand how these drugs work and what risks are involved for anyone who uses them?

Let Them Eat Prozac explores the history of SSRIs—from their early development to their latest marketing campaigns—and the controversies that surround them. Initially, they seemed like wonder drugs for those with mild to moderate depression. When Prozac was released in the late 1980s, David Healy was among the psychiatrists who prescribed it. But he soon observed that some of these patients became agitated and even attempted suicide. Could the new wonder drug actually be making patients worse?

Healy draws on his own research and expertise to demonstrate the potential hazards associated with these drugs. He intersperses case histories with insider accounts of the research leading to the development and approval of SSRIs as a treatment for depression. Let Them Eat Prozac clearly demonstrates that the problems go much deeper than a side-effect of a particular drug. The pharmaceutical industry would like us to believe that SSRIs can safely treat depression, anxiety, and a host of other mental problems. But, as Let Them Eat Prozac reveals, this "cure" may be worse than the disease.

.
Price: $9.95 [Notify me when price goes down.]

All of us have experienced, at one time or another, the temporary inflammation and pain of a minor injury. But those who suffer from chronic inflammation--whether the result of an injury or a biological disorder--and its coincidental pain are all too aware of the frequently crippling and debilitating effects of these conditions. 

In The Cox-2 Connection, pharmacist and naturalist James B. LaValle shares a thorough overview of treatment options for a variety of disorders for which inflammation is a primary symptom--from osteoarthritis, bursitis, and fibromyalgia to rheumatoid arthritis, gout and dysbiosis. He clearly explains the physiological mechanism that leads to inflammation and pain and includes an in-depth section on pain-management strategies useful for anyone who is experiencing this discomfort, whether temporary or chronic.

Cox-2--or cyclooxygenase-2--is the key enzyme responsible for the body's inflammation and pain response in conditions such as arthritis and bursitis, and it is also linked to the inflammation that may play a significant role in the progression of Alzheimer's and cancer. The Cox-2 Connection, however, goes further than other pain management books by dealing with not only the synthetic, anti-inflammatory Cox-2 inhibitors, such as Celebrex and Vioxx, but also with their natural counterparts that have been used for thousands of years by people all over the world. The author thoughtfully evaluates the effectiveness of these inhibitors as well as their side effects and presents exciting new studies that indicate their possible role in preventing Alzheimer's and cancer. 

The Cox-2 Connection is an essential and timely reference for anyone trying to understand and manage inflammation and pain and make sense of the exploding availability and potential of ways to deal with them.

.
Price: $0.59 [Notify me when price goes down.]

Vital information for discovering and optimizing new drugs
"Understanding the data and the experimental details that support it has always been at the heart of good science and the assumption challenging process that leads from good science to drug discovery. This book helps medicinal chemists and pharmacologists to do exactly that in the realm of enzyme inhibitors."
-Paul S. Anderson, PhD
This publication provides readers with a thorough understanding of enzyme-inhibitor evaluation to assist them in their efforts to discover and optimize novel drug therapies. Key topics such as competitive, noncompetitive, and uncompetitive inhibition, slow binding, tight binding, and the use of Hill coefficients to study reaction stoichiometry are all presented. Examples of key concepts are presented with an emphasis on clinical relevance and practical applications.
Targeted to medicinal chemists and pharmacologists, Evaluation of Enzyme Inhibitors in Drug Discovery focuses on the questions that they need to address:
* What opportunities for inhibitor interactions with enzyme targets arise from consideration of the catalytic reaction mechanism?
* How are inhibitors evaluated for potency, selectivity, and mode of action?
* What are the advantages and disadvantages of specific inhibition modalities with respect to efficacy in vivo?
* What information do medicinal chemists and pharmacologists need from their biochemistry and enzymology colleagues to effectively pursue lead optimization?
Beginning with a discussion of the advantages of enzymes as targets for drug discovery, the publication then explores the reaction mechanisms of enzyme catalysis and the types of interactions that can occur between enzymes and inhibitory molecules that lend themselves to therapeutic use. Next are discussions of mechanistic issues that must be considered when designing enzyme assays for compound library screening and for lead optimization efforts. Finally, the publication delves into special forms of inhibition that are commonly encountered in drug discovery efforts, but can be easily overlooked or misinterpreted.
This publication is designed to provide students with a solid foundation in enzymology and its role in drug discovery. Medicinal chemists and pharmacologists can refer to individual chapters as specific issues arise during the course of their ongoing drug discovery efforts..
Price: $79.91 [Notify me when price goes down.]

In 1961, twenty-eight-year-old Dr. Judah Folkman saw something while doing medical research in a United

States navy lab that gave him the first glimmering of a wild, inspired hunch. What if cancerous tumors, in order to expand, needed to trigger the growth of new blood vessels to feed themselves? And if that was true, what if a way could be found to stop that growth? Could cancers be starved to death? Dr. Folkman had ample reason to be self confident — second in his class at Harvard Medical School, he was already considered one of the most promising doctors of his generation. But even he never guessed that his idea would eventually grow into a multibillion-dollar industry that is now racing through human trials with drugs that show unparalleled promise of being able to control cancer, as well as other deadly diseases.

For the creation of this book, Dr. Judah Folkman cooperated fully and exclusively with acclaimed science writer Robert Cooke. He granted Cooke unlimited interviews, showed him diaries and personal papers, and threw open the doors of his lab. The result is an astonishingly rich and candid chronicle of one of the most significant medical discoveries of our time and of the man whose vision and persistence almost single-handedly has made it possible.

Dr. Folkman's radical new way of thinking about cancer was once considered preposterous. So little was known about how cancer spreads and how blood vessels grow that he wasn't even taken seriously enough to be considered a heretic. Other doctors shook their heads at the waste of a great mind, and ambitious young medical researchers were told that accepting a position in Folkman's lab would be the death of their careers. Now, though, the overwhelming majority of experts believes that the day will soon come when antiangiogenesis therapy supplants the current more toxic and less-effective treatments — chemotherapy, radiation, and surgery-as the preferred method of treatment for cancer in patients around the world, and Dr. Folkman's breakthrough will come to be taken for granted the way we now take for granted the polio vaccine and antibiotics.

Dr. Folkman's War brilliantly describes how high the odds are against success in medical research, how vicious the competition for grants, how entrenched the skepticism about any genuinely original thinking, how polluted by politics and commerce the process of getting medicine into patients' hands. But it also depicts with rare power how exalted a calling medicine can be and how for the rare few—the brilliant, the tireless, and the lucky — the results of success can be world-changing..
Price: $5.98 [Notify me when price goes down.]

Firsthand accounts of people who have taken the controversial, life-changing drug reveal the positive and profound benefits and transformations experienced and identify some of the problems that may be helped by Prozac. $20,000 ad/promo..
Price: $0.66 [Notify me when price goes down.]

Outlines strategies for stimulating capillary formation in hypoxia and ischemia and inhibiting it in cancer, diabetes, and chronic inflammation. This state-of-the-science reference highlights recent progress in the ways to promote formation of new blood vessels in ischemic/hypoxic tissue and the means to stifle capillary growth and development in solid tumors, diabetic retinopathy, and chronic immuno/inflammatory disorders such as rheumatoid arthritis and psoriasis. Emphasizes practical clinical applications derived from the latest angiogenesis research. Written by over 80 leading international experts, Angiogenesis in Health and Disease · examines new angiogenic regulators such as angiopoietins and TIE-receptors · describes angiogenic genes such as thymosine B-4, EDG-1, and ARNT proteins · analyzes the role of vascular endothelial growth factor (VEGF) in capillary sprouting · investigates behaviors of endogenous agents of angiogenesis, including cytokines, hormones, chemokines, and peptide and hematopoietic growth factors · explores mechanisms for ameliorating or preventing vascular occlusive disease by induction of collateral artery growth · explains differences in conditions that prompt angiogenesis and arteriogenesis · reviews transgenic and knock-out mice, receptor protein mutations, and other emerging technologies · evaluates angiogenic inhibitors such as angiostatin and endostatin · and more! Containing over 3000 references, tables, drawings, and photographs, Angiogenesis in Health and Disease deserves a prominent place on the bookshelves of cardiologists, oncologists, physiologists, hematologists, molecular and cell biologists, biochemists, pharmacologists, rheumatologists, vascular surgeons, and upper-level undergraduate, graduate, and medical school students in these disciplines..
Price: $47.98 [Notify me when price goes down.]

This reference describes almost 3800 trade name and generic chemicals used to prevent and remove corrosion and rust.Coverage includes chemicals that function as:Acid inhibitors; Antideposition aids; Corrosion inhibitors; Corrosion and rust intermediates; Dispersants; Film-formers; Rust inhibitors; Rust removers; Neutralizers; Metal deactivators; Oxygen scavengers; pH adjusters; Phosphatizers; Protectants; Scale inhibitors; Water repellentsIn these Application Areas:Boiler water systems; Cement/Concrete; Consumer packaging; Cooling water systems; Dry cleaning processes; Ferrous/Nonferrous metals; Food processing; Fuel additives; Industrial/Consumer equipment; Lubricating systems Metalworking fluids; Oil field applications; Paints/Coatings Pigments Pulp/Paper processing; Wastewater treatment.
Price: $447.75 [Notify me when price goes down.]